Ming Li

Professor

University of Southern California
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Impact of steroids on CD8 + T-cell differentiation and predictive value of the CX3CR1 score in patients with NSCLC treated with ICI therapy. A, Violin plot with median (red solid line) and the top and bottom quartiles (red dotted line) showing the frequency of PB CX3CR1 + CD8 + T cells in patients who were or were not on steroids at baseline. P value was calculated by a two-tailed Mann–Whitney U test. B, ORR for patients who were or were not on steroids at baseline and the maximal percent change of the CX3CR1 + subset among PB CD8 + T cells from baseline (CX3CR1 score) at 9 weeks. The ORR was analyzed by the Fisher exact test. C, CX3CR1 score in responders (CR/PR) and nonresponders (SD/PD) who were or were not on steroids at baseline. The non-steroid group was separated into anti–PD-1 therapy (black line) and chemo-immunotherapy (red line). CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

Year:

2025

Corticosteroids are frequently prescribed to patients with non–small cell lung cancer (NSCLC) for palliation of cancer-related symptoms; however, the potential impact of baseline steroid use on immune checkpoint inhibitor (ICI) therapy and its underlying mechanisms remain unclear. In this study, we evaluated clinical outcomes of 277 patients with NSCLC treated with ICI therapy at two academic institutions. Twenty-one patients (8%) were taking steroids at the start of ICIs. Patients on baseline steroids had a lower overall response rate with markedly shorter progression-free survival and overall survival compared with those not receiving steroids. In multivariate analysis, steroid use was the only significant independent risk factor for disease progression and mortality in both independent cohorts, Roswell Park Comprehensive Cancer Center ( n = 88) and University of Southern California ( n = 189). A baseline peripheral blood neutrophil-to-lymphocyte ratio + CD8 + T cells was substantially lower in patients on steroids. Using a bedside-to-bench approach, we found that concurrent steroid use significantly decreased antitumor efficacy of anti–PD-1 therapy and attenuated the increase of CX3CR1 + CD8 + T cells in mice bearing MC38 tumors whereas discontinuation of steroid at the start of treatment did not make a negative impact on survival. Collectively, baseline steroid use was associated with worse outcomes and decreased frequency of circulating differentiated effector T cells in patients with NSCLC. Caution should be taken when interpreting the results from circulating immune-related biomarkers in patients on steroids. Significance: The impact of corticosteroids, widely prescribed for palliation of cancer-related symptoms, on ICI therapy remains unclear. This study shows that baseline steroid use is a negative independent prognostic factor in patients with NSCLC undergoing ICI therapy and provides insights into the decreased T-cell effector differentiation and utility of predictive blood-based markers by steroids.

Year:

2025

The impact of baseline steroid use on predictive and prognostic values of NLR in patients with NSCLC treated with ICI therapy. A–H, ORR, PFS, and OS of patients at RPCCC and USC treated with ICI therapy according to PB-high (≥5) or-low ( A , B , E , and F ) was analyzed by the Fisher exact test. P values for PFF and OS ( C , D , G , and H ) were calculated by a log-rank (Mantel–Cox) test. mOS, median OS; mPFS, median PFS.

Year:

2025

The use of corticosteroids at the initiation of ICI therapy correlates with decreased ORR and worse prognosis in patients with NSCLC. A–D, ORR, PFS, and OS of patients at RPCCC ( A and C ) and USC ( B and D ) treated with ICI therapy on the basis of baseline steroid use. The ORR was analyzed by the Fisher exact test. P values for PFF and OS were calculated by a log-rank (Mantel–Cox) test. mOS, median OS; mPFS, median PFS.

Year:

2025

Continued use of corticosteroids during anti–PD-L1 therapy correlates with decreased survival in a preclinical model. A, Experimental set-up. Mice bearing MC38 tumors were treated with anti–PD-L1 or isotype antibody. Mice were administered with dexamethasone or PBS intraperitoneally before (day −12 to 0) and/or during (day 0–14) anti–PD-L1 therapy. B, Tumor growth curves (mean) and survival curves in MC38 tumor-bearing mice in different treatment groups as indicated. n = 5 to 6 mice. **, P P values were determined by a log-rank (Mantel–Cox) test. C, Frequency of the CX3CR1 + subset in PB CD8 + T cells. PB was collected on day 14. n = 5 to 6 mice. P values were determined by the Kruskal–Wallis test with Dunn multiple comparisons. Data are presented as mean ± SEM. Ab, antibody; dex, dexamethasone; i.p., intraperitoneal; NS, not significant; αPD-L1, anti–PD-L1.

Year:

2025

Collaborators (6)

Fumito Ito

Professor

University of Southern California

UNITED STATES
View details

Jorge Nieva

Professor of Clinical Medicine

University of Southern California

UNITED STATES
View details

Brahm Segal

Chair

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Ryutaro Kajihara

Kumamoto University

JAPAN
View details

Angelina Lim

University of Southern California

UNITED STATES
View details

Junko Matsuzaki

Research Professor

University of Chicago

UNITED STATES
View details